Details of the Drug

General Information of Drug (ID: DMM75WZ)

• Drug Name: Chloroxylenol
• Synonyms: Benzytol; Chloro-xylenol; Chloroxylenolum; Chlorxylenolum; Clorossilenolo; Cloroxilenol; Desson; Dettol; Dettol, liquid antiseptic; Espadol; Husept Extra; Nipacide MX; Ottasept; Ottasept Extra; Parametaxylenol; Phenol, 4-chloro-3,5-dimethyl-; RBA 777; Septiderm-Hydrochloride; Willenol V; chloroxylenol; p-Chloro-3,5-xylenol; p-Chloro-m-xylenol; parachlorometaxylenol; 2-Chloro-5-hydroxy-m-xylene; 2-Chloro-m-xylenol; 3,5-Dimethyl-4-chlorophenol; 4-Chloro-3,5-dimethylphenol; 4-Chloro-3,5-xylenol; 4-Chloro-m-xylenol; 88-04-0; PCMX

Indication

Disease Entry	ICD 11	Status	REF
Pseudomonas infection	1B92	Investigative	[1]

• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 156.61
  Topological Polar Surface Area (xlogp); 2
  Rotatable Bond Count (rotbonds); 0
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 1
• ADMET Property:
  Clearance: The clearance of drug is 13.76 L/h [2]
  Half-life: The concentration or amount of drug in body reduced by one-half in 10 hours (in healthy adults) [3]
  Metabolism: The drug is metabolized via the kidney [3]
  Vd: The volume of distribution (Vd) of drug is 22.45 L [4]
• Chemical Identifiers:
  Formula: C8H9ClO
  IUPAC Name: 4-chloro-3,5-dimethylphenol
  Canonical SMILES: CC1=CC(=CC(=C1Cl)C)O
  InChI: OSDLLIBGSJNGJE-UHFFFAOYSA-N
  InChIKey: 1S/C8H9ClO/c1-5-3-7(10)4-6(2)8(5)9/h3-4,10H,1-2H3
• Cross-matching ID:
  PubChem CID: 2723
  ChEBI ID: CHEBI:34393
  CAS Number: 88-04-0
  DrugBank ID: DB11121
  INTEDE ID: DR0302

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2E1 (CYP2E1)	DEVDYN7	CP2E1_HUMAN	Substrate	[5]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[5]
Cytochrome P450 2A6 (CYP2A6)	DEJVYAZ	CP2A6_HUMAN	Substrate	[5]

References

• [1] National Center for Advancing Translational Science-Inxight: drug (0F32U78V2Q)
• [2] Zondek B, Shapiro B: Fate of halogenated phenols in the organism. Biochem J. 1943;37(5):592-5.
• [3] Electronic Medicines Compendium: Dettol (Chloroxylenol) Antiseptic Cream Monograph
• [4] Exponent FDA Consumer Antispetics Rule: FDA Request for Data on Safety and Efficacy of Chloroxylenol
• [5] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [6] Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
• [7] Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
• [8] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [9] Psychotropic drug interactions with valproate. Clin Neuropharmacol. 2005 Mar-Apr;28(2):96-101.
• [10] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [11] Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
• [12] CYP2A6- and CYP2A13-catalyzed metabolism of the nicotine delta-5'(1')iminium ion. J Pharmacol Exp Ther. 2012 Nov;343(2):307-15.
• [13] Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
• [14] Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
• [15] CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
• [16] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [17] Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
• [18] Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
• [19] Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
• [20] Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
• [21] Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
• [22] Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
• [23] Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
• [24] Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
• [25] A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
• [26] The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
• [27] Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
• [28] Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
• [29] CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.